Achieve Life Sciences Inc
$ 4.39
4.03%
24 Feb - close price
- Market Cap 224,647,000 USD
- Current Price $ 4.39
- High / Low $ 4.54 / 4.23
- Stock P/E N/A
- Book Value 0.64
- EPS -1.35
- Next Earning Report 2026-03-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.65 %
- ROE -1.61 %
- 52 Week High 6.03
- 52 Week Low 1.84
About
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and markets cytisinicline for smoking and nicotine addiction cessation in the United States and internationally. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$15.38
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-26 | 2024-11-07 | 2024-08-13 | 2024-05-09 | 2024-03-13 | 2023-11-09 | 2023-08-14 | 2023-05-09 | 2023-03-16 |
| Reported EPS | -0.28 | -0.37 | -0.37 | -0.36 | -0.36 | -0.25 | -0.26 | -0.26 | -0.34 | -0.43 | -0.5 | -0.83 |
| Estimated EPS | -0.24 | -0.37 | -0.3657 | -0.36 | -0.26 | -0.23 | -0.24 | -0.31 | -0.38 | -0.42 | -0.69 | -0.83 |
| Surprise | -0.04 | 0 | -0.0043 | 0 | -0.1 | -0.02 | -0.02 | 0.05 | 0.04 | -0.01 | 0.19 | 0 |
| Surprise Percentage | -16.6667% | 0% | -1.1758% | 0% | -38.4615% | -8.6957% | -8.3333% | 16.129% | 10.5263% | -2.381% | 27.5362% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-10 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.27 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ACHV
2026-02-16 04:27:39
Achieve Life Sciences announced a $45 million capital raise through a securities offering, which led to a decrease in its stock price. The funding aims to support the company's initiatives. Investors reacted negatively to the dilution potential of the offering.
2026-02-08 09:28:57
Achieve Life Sciences (NASDAQ:ACHV) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $15.50. The clinical-stage biopharmaceutical company, developing cytisinicline for smoking cessation, saw its shares open at $4.25, up 7.6%. Despite missing quarterly EPS estimates, institutional investors have shown increased interest, with significant stake increases reported.
2026-02-05 09:18:29
Achieve Life Sciences (NASDAQ:ACHV) stock successfully crossed above its 200-day moving average, reaching $4.26 while the 200-day average stands at $3.94. The company has received a "Moderate Buy" rating from analysts with an average price target of $15.50, despite missing recent earnings estimates. Institutional investors have shown mixed activity, with some increasing and some reducing their stakes in the biopharmaceutical company which focuses on developing cytisinicline for smoking cessation.
2026-02-02 19:32:00
This article summarizes a bullish thesis on Achieve Life Sciences, Inc. (ACHV), focusing on the potential FDA approval of its smoking cessation drug, cytisinicline. The drug is positioned as a superior alternative to older treatments due to its efficacy and tolerability, with a regulatory decision expected by June 20, 2026. ACHV also explores cytisinicline for vaping cessation, a market with no current FDA-approved therapies, and is transitioning from a development-stage to a commercial-stage company.
2026-02-02 19:32:00
Achieve Life Sciences, Inc. (ACHV) is highlighted as a company with significant upside potential, primarily driven by its drug cytisinicline, which awaits FDA approval for smoking cessation. This non-nicotine therapy is positioned as a superior alternative to older drugs, with a decision expected by June 20, 2026. The article also notes ACHV's pursuit of approval for vaping cessation, a market with no existing FDA-approved therapies, and its financial runway through the FDA decision.
2026-02-01 20:57:18
Achieve Life Sciences announced that its board of directors approved stock option grants for five new employees under its 2024 Equity Inducement Plan. These options cover 115,000 shares of common stock, with an exercise price matching the closing price on January 28, 2026, and a four-year vesting schedule. The grants aim to attract talent and support the company's focus on developing cytisinicline for nicotine dependence, including both smoking and vaping cessation.
